

GUFIC BIOSCIENCES LIMITED

Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069
(CIN- L24100MH1984PLC033519)

Website - www.gufic.com, email - info@guficbio.com, Ph-022 67261000, Fax - 022 67261068

(Rs. in Lakhs except EPS)

Statement of Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2021

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-Dec-21	30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	INCOME						
	a Revenue from operations	17,206.54	19,413.94	16,655.65	61,696.25	35,576.95	48,769.87
	b Other income	153.03	30.50	3.33	306.35	307.72	373.29
	Total Income	17,359.57	19,444.44	16,658.97	62,002.60	35,884.67	49,143.16
2	Expenses						
	a Cost of materials consumed	7,504.09	8,895.08	7,264.25	27,660.75	16,387.76	21,345.17
	b Purchase of stock-in-trade	1,106.02	1,873.17	1,708.81	6,523.30	1,494.73	2,255.25
	c Changes in inventories of finished goods, work-in-progress and stock-in-trade	175.13	(282.09)	393.12	(135.43)	608.47	1,428.79
	d Employee benefits expense	2,070.70	2,011.63	1,861.53	6,630.19	4,895.89	6,621.80
	e Finance cost	103.22	154.87	377.86	379.03	1,076.13	1,363.33
	f Depreciation and amortisation expense	448.41	419.68	322.25	1,280.67	1,182.53	1,630.76
	g Other expenses	3,078.82	3,333.19	2,685.84	9,597.89	6,172.86	8,726.91
	Total Expenses	14,486.39	16,405.54	14,613.67	51,936.40	31,818.37	43,372.01
3	Total Profit before exceptional items and tax (1-2)	2,873.18	3,038.90	2,045.30	10,066.20	4,066.30	5771.15
4	Exceptional items	-	-	-	-	-	-
5	Total Profit Before Tax	2,873.18	3,038.90	2,045.30	10,066.20	4,066.30	5771.15
6	Tax Expense						
	Current tax	727.00	767.00	475.81	2,550.00	914.81	1,719.82
	Deferred tax	42.92	(61.72)	21.47	(41.39)	13.83	201.14
	Short/(excess) tax provision of earlier years	-	-	1.54	-	1.54	(572.97)
	Total Tax Expenses	769.92	705.28	498.82	2,508.61	930.18	1,347.99
7	Total Profit for Period	2,103.26	2,333.62	1,546.48	7,557.59	3,136.12	4,423.16
8	Other Comprehensive Income (OCI)						
	Items that will not be reclassified to profit or loss	-	-	-	-	-	38.51
	Less: Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	(11.41)
	Other Comprehensive Income (net of taxes)	-	-	-	-	-	27.10
9	Total Comprehensive Income	2,103.26	2,333.62	1,546.48	7,557.59	3,136.12	4450.26
10	Reserves						16,374.20
11	Details of Equity Share Capital						
	Paid-up equity share capital	969.45	969.45	969.45	969.45	969.45	969.45
	Face value of equity share capital (Rs.)	1.00	1.00	1.00	1.00	1.00	1.00
12	Earning Per Equity Share						
	i Basic earnings per share from continuing and discontinued operations	2.17	2.41	1.60	7.80	3.23	4.56
	ii Diluted earnings per share from continuing and discontinued operations	2.17	2.41	1.60	7.80	3.23	4.56

Notes:

- The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of companies Act, 2013, read with rules issued thereunder.
- The above results for the quarter ended December 31, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 09, 2022. The Statutory Auditors have carried out limited review of the results for quarter and nine months ended December 31, 2021.
- The Company's business activity falls within a single operating segment i.e. Pharmaceuticals.
- Previous year/quarters figures have been regrouped/reclassified, wherever necessary.

FOR GUFIC BIOSCIENCES LIMITED

Pranav J. Choksi

PRANAV J. CHOKSI
CEO & WHOLE TIME DIRECTOR
DIN : 00001731

PLACE : MUMBAI
DATE : 09/02/2022



For identification purposes only.

Pranav J. Choksi
09/02/2022



MITTAL AGARWAL & COMPANY

CHARTERED ACCOUNTANTS

Limited Review Report on the Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Gufic Biosciences Limited

- 1) We have reviewed the accompanying statement of Unaudited Financial Results of **Gufic Biosciences Limited** (the "Company") for the quarter ended 31 December 2021 and year to date results for the period from 1 April 2021 to 31 December 2021 (the "Statement").
- 2) This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit, and accordingly, we do not express an audit opinion.

Emphasis of Matter

- 4) The Board of Directors of the Company at its Board meeting held on 25 March 2019 approved the Scheme of Amalgamation of Gufic Lifesciences Private Limited ("Transferor Company") with the Company and their respective shareholders and creditors ("Scheme"), subject to sanction of the regulatory authorities. The Company has received approval from all the regulatory authorities to give effect to the said scheme of merger considering 01 January 2019 as date of merger. Further, to give accounting effect of the merger in the financial results, all the corresponding published figures for the quarter and nine months ended 31 December 2020 have been accordingly restated.

Attention is drawn to the fact that the comparative financial information to the extent it relates to the Transferor Company for corresponding quarter and nine months ended 31 December 2020 as reported in the financial results have been certified by the Management and were not subjected to our review.

Our opinion is not modified in respect of the above matter.





MITTAL AGARWAL & COMPANY


CHARTERED ACCOUNTANTS

- 5) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mittal Agarwal & Company
Chartered Accountants
(Firm Registration No. 131025W)



Place: Mumbai
Dated: 09/02/2022
UDIN: 22135505ABAHKV1077


Piyush Agarwal
Partner
Membership No. 135505